Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 7/20 | 0.69 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.42 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.42 |
| ▸ | NCF1 | P14598 | 4/20 | 0.42 |
| ▸ | ILK | Q13418 | 1/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | FLT1 | P17948 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | HPGDS | O60760 | 2/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | FBP1 | P09467 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7140894 | 0.96 | EGFR (0.63) | EGFRKDM1ANCF1ILKAPP | |
| SCHEMBL29831918 | 0.84 | EGFR (0.59) | EGFRNCF1 | |
| SCHEMBL30504578 | 0.82 | EGFR (0.70) | EGFRPDGFRBPDGFRANCF1HDAC1 | |
| SCHEMBL4649110 | 0.82 | EGFR (0.70) | EGFRPDGFRBPDGFRANCF1HDAC1 | |
| SCHEMBL30241125 | 0.82 | EGFR (1.00) | EGFRPDGFRBPDGFRAHPGDS | |
| SCHEMBL668493 | 0.82 | EGFR (1.00) | EGFRPDGFRBPDGFRAHPGDS | |
| SCHEMBL29517021 | 0.82 | EGFR (1.00) | EGFRPDGFRBPDGFRAHPGDS | |
| SCHEMBL6489451 | 0.81 | EGFR (0.59) | EGFRPDGFRBPDGFRANCF1HDAC1 | |
| Hydrochloric Acid SCHEMBL28023744 | 0.80 | EGFR (0.96) | EGFRPDGFRBPDGFRAHPGDS | |
| SCHEMBL5682759 | 0.79 | EGFR (0.56) | EGFRNCF1HDAC1HDAC6HDAC5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3436446-B1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2023-06-07 | — | — | EP | disclosed |
| EP-2569298-A1 | NOVEL CCR2 RECEPTOR ANTAGONISTS, METHOD FOR PRODUCING THE SAME, AND USE THEREOF AS MEDICAMENTS | Boehringer Ingelheim International GmbH (DE) | 2013-03-20 | — | — | EP | disclosed |
| WO-2011141474-A1 | NOVEL CCR2 RECEPTOR ANTAGONISTS, METHOD FOR PRODUCING THE SAME, AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-17 | — | — | WO | disclosed |
| EP-1799191-A1 | MODIFYING SURFACES OF LACTOSE SERVING AS AN AUXILIARY AGENT TO BE USED FOR POWDER INHALANTS | Boehringer Ingelheim International GmbH (DE) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006037738-A1 | MODIFYING SURFACES OF LACTOSE SERVING AS AN AUXILIARY AGENT TO BE USED FOR POWDER INHALANTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-04-13 | — | — | WO | disclosed |